Cancer Control and Prevention Protocols
Leukemia, Myelodysplastic Syndrome
The National Myelodysplastic Syndromes (MDS) Study
Eligible for screening study DCP 001
This protocol has additional regulatory requirements to be completed prior to registering any patients at your site. Please contact Amber Boerner at 406-969-6067 or email@example.com for additional information.
Suspension to enrollment of new participants and follow-up research sample collection and shipment is lifted effective May 18, 2020, for NHLBI-MDS. Refer to memo dated March 27, 2020, on conducting remote follow-up data for enrolled participants.